Ada Vera
Podiatrist · Las Vegas, NVNPI 1902942725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Smith+Nephew at 34.5% of the total. 2025 is the largest year on record at $1,204, 2.2 times the $544 reported in 2019.
Across 266 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$2K
- Kerecis Limited$530
- Paratek Pharmaceuticals, Inc.$452
- Mimedx Group, Inc.$411
- Tactile Systems Technology Inc$374
- Bioventus LLC$256
- plus $1K from 22 others
What the payments were for
- Food & beverage$5,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 132 | $1,797 |
| Kerecis Limited | 7 | $530 |
| Paratek Pharmaceuticals, Inc. | 26 | $452 |
| Mimedx Group, Inc. | 8 | $411 |
| Tactile Systems Technology Inc | 31 | $374 |
| Bioventus LLC | 10 | $256 |
| Lifenet Health | 3 | $225 |
| Koya Medical, Inc. | 1 | $161 |
| Melinta Therapeutics, LLC | 10 | $161 |
| AbbVie | 6 | $129 |
| Urgo Medical North America, LLC | 4 | $126 |
| Convatec Inc. | 5 | $102 |
| Organogenesis Inc. | 3 | $81 |
| Solventum Corporation | 2 | $70 |
| Zyla Life Sciences, Inc. | 3 | $37 |
| GSK | 2 | $37 |
| Next Science LLC | 2 | $36 |
| Mayne Pharma Commercial LLC | 1 | $35 |
| Polarityte, Inc. | 1 | $32 |
| Sandoz | 1 | $23 |
| OVIK Health, LLC | 1 | $19 |
| Ossur Americas, Inc. | 1 | $19 |
| Innovation Technologies Inc | 1 | $18 |
| Bsn Medical Inc | 1 | $18 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $16 |
| Merck | 1 | $15 |
| Forte Bio-pharma LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$923
- Kerecis SurgiClose$483
- Dayspring$483
- Grafix$278
- Kerecis Omega3 SurgiClose$271
- TheraGenesis Wound Matrix$177
- Koya Medical$161
- Kerecis Omega3 GraftGuide$159
- PICO7$121
- Kerecis GraftGuide$121
- Santyl$111
How this compares
$5,211 in reported general payments places this provider in the 75th percentile of 44 podiatrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 305 | $7,147 |
| Gentamicin Sulfate | 192 | $6,873 |
| Ciclopirox | 197 | $5,133 |
| SantylCollagenase Clostridium Hist. | 11 | $4,413 |
| Ammonium Lactate | 165 | $3,285 |
| Fluorouracil | 31 | $2,533 |
| Clobetasol Propionate | 13 | $1,283 |
| Lidocaine | 25 | $1,088 |
| Pregabalin | 108 | $960 |
| Terbinafine Hcl | 73 | $724 |
| Mupirocin | 88 | $621 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $475 |
| Nystatin | 18 | $383 |
| Gabapentin | 79 | $371 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 35 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,797 | $4,41311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 podiatrist providers in Nevada.
Other podiatrist in Las Vegas
- Anthony RicciardiLas Vegas$498K
- Jeremy AndersonLas Vegas$72K
- He XuLas Vegas$54K
- Peter BregmanLas Vegas$18K
- Anmy VuLas Vegas$15K
- Ai Quoc HellerLas Vegas$8K
- John CadeLas Vegas$6K
- Michael ChildsLas Vegas$4K
- Justin ColarcoLas Vegas$2K
- Sofia HossainLas Vegas$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.